Open AccessCyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis: Experience from a tertiary care centre of South Rajasthan
Author(s) -
Manisha Balai,
Manju Meena,
Asit Mittal,
Lalit Gupta,
Ashok Kumar Khare,
Sharad Mehta
Publication year - 2021
Publication title -
indian dermatology online journal
Language(s) - English
Resource type - Journals
eISSN - 2249-5673
pISSN - 2229-5178
DOI - 10.4103/idoj.idoj_326_20
Subject(s) - toxic epidermal necrolysis , medicine , tolerability , mucocutaneous zone , drug , prospective cohort study , tertiary care , erythroderma , dermatology , disease , adverse effect , pharmacology
Stevens-Johnson syndrome and toxic epidermal necrolysis are severe, life-threatening mucocutaneous drug reactions with a high morbidity and mortality that require immediate medical care. Several immunomodulatory drugs are used for the treatment but evidence of their efficacy is limited. Cyclosporine has recently been found to have a promising role in SJS/TEN owing to its potent antiapoptotic activity.